Neurofix
Discovers and develops molecules for the treatment of pathologies of the central nervous system.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €750k | Seed | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | (100 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | 100 % | - | (4357 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 66 % | - | (226 %) | - | (182 %) | (7435 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Neurofix Pharma, a Spanish biotechnology firm founded in 2015, is focused on the development of lipid-based therapies for neurological disorders. The company operates from the Science Park of the University of Salamanca and was established by a team of experienced scientists and executives, with Miguel Ángel Ávila serving as the CEO and a co-founder. Ávila holds degrees in Agricultural Engineering and an MBA, and has extensive experience in managing R&D projects.
The company's primary business is the research and development of drugs to treat diseases of the Central Nervous System. Neurofix's business model revolves around advancing its drug candidates through clinical trials to eventually secure regulatory approval and commercialize them, addressing unmet needs in the neurology market. The company has secured funding through various rounds, including venture capital and equity crowdfunding, to finance its research and clinical development activities.
Neurofix's lead product candidate is NFX88, a first-in-class drug designed to alleviate neuropathic pain in patients with spinal cord injuries (SCI). This condition currently lacks adequate treatment options. NFX88, with its unique lipid-based structure (2-hydroxyoleic acid), targets cell membranes to alter their properties. This mechanism reduces the production of pro-inflammatory substances and increases molecules associated with neuronal repair, ultimately aiming to reduce the pain itself rather than just managing symptoms. The drug has successfully completed Phase I and Phase IIA clinical trials, demonstrating a strong safety and efficacy profile. The company is now preparing for the final Phase IIB/III trials across multiple European hospitals, which is the last step before potential commercialization. Beyond NFX88, Neurofix's pipeline includes NFX81 for treating paralysis from SCI and NFX91 for sleep disturbances.
Keywords: Neurofix Pharma, biotechnology, neuropathic pain, spinal cord injury, NFX88, drug development, clinical trials, central nervous system, lipid-based therapies, 2-hydroxyoleic acid, neurorepair, neuropharmacology, orphan drug, Salamanca, Miguel Ángel Ávila, pharmaceutical research, neurology, pain management, first-in-class drug